Additionally, four cohort studies examined postoperative VTE risk in T2DM or morbidly obese patients receiving GLP-1 receptor agonists.44, 45, 46, 47The study by Elsabbagh et al.44investigated DVT or PE risk within 90 days after total shoulder arthroplasty and found no significant difference in DVT risk (odds ratio [OR] 1.27, 95% CI 0.82–1.91) or PE risk (OR 0.70, 95% CI 0.40–1.26) between GLP-1 receptor agonist users and non-users. This evidence concerns the gene GLP1R and deep vein thrombosis.